# MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria

> **NCT02880241** · PHASE2 · TERMINATED · sponsor: **Medicines for Malaria Venture** · enrollment: 8 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** MMV390048

## Key facts

- **NCT ID:** NCT02880241
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-20
- **Primary completion:** 2018-01-01
- **Final completion:** 2018-09-24
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Due to a Medicines for Malaria Venture (MMV) strategic business decision
- **Last updated:** 2021-12-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02880241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02880241, "MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02880241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*